Anesthesia Cardiology Articles Ivabradine Alerts Preliminary Study Results SIGNIFY Nephrology Gastroenterology Infectious fungi Pharmacology Neumologia # 1094 (Untitled) Neurology The use of benzodiazepines is associated with the development of Alzheimer Cardiology Guidelines (Guidelines) brady / tachyarrhythmias Atrial Fibrillation Insuf disease. heart (Guide) Preventing Anemia in Patients With Heart Disease Cholesterol Treatment of Peripheral Artery Disease Valvular Heart Disease Vascular TEP Nephrology (guides) Agenda SEN Asthma COPD Pulmonary Neurology (guides) Hemorrhagic Stroke Ischemic Stroke CPR (ILCOR 2010) Sepsis (guides) SSC 2012 Protocols Cardiology Measurement of central venous pressure in the perioperative management recommendations of the patient with macapasos / ICD / ICD-CRT allergies Digestive Surgery Cardiac Surgery Intensive Metabolic-Renal Pulmonology Neurology Obstetric critical cardiopulmonary allergies resuscitation Summary of current CPR recommendations (ILCOR 2010) Rheumatology Sepsis Protocol in Ebola virus infection Toxicology Review Topics Marcapasoterapia Cardiology Gastroenterology Infectious Metabolic-Renal Rheumatology allergies Neurology allergies Obstetrics Review More Calculators allergies Online Anion Gap Bicarbonate Deficit Apache II infusion dose as Gradient Alveolus-arterial blood gas O2 Intravenous infusion Corrected QT SOFA Consents Policy Forum Tutorials allergies Contact cookies Clinical allergies Echocardiography allergies 1. Standard 2. Measurements 3. Projections CONTRACTILITY And SLVF Utilities Recommended Websites
It has recently been commercialized a new antibiotic for C. difficile disease called fidaxomina. This is a non-absorbable antibiotic that inhibits macrocytic bacterial RNA polymerase and exhibits excellent bactericidal activity allergies in vitro. Reaches high concentrations in fecal and virtually allergies undetectable levels in plasma, and has not been reported emergence of resistance to one drug. Fidaxomicin offers the advantage over other antibiotics, to respect the colonic flora, since it has no activity against other bacteria of the same members as Gram-negative rods, and being able to inhibit the sporulation of C. difficile, so their use is associated with improved recurrence rate one. The phase III studies published in the fidaxomicin (200 mg orally every 12 hours for 10 days) versus vancomycin (125 mg every 6 hours for 10 days) compared demonstrated non-inferiority in terms of cure rates at the end treatment and overall superiority of fidaxomicin response at 28 days after the end due to a reduction in recurrence rates 2, 3 (no proven benefit in patients infected with the NAP1 strain). Fidaxomicin has also demonstrated superior compared to vancomycin in terms of preventing allergies a second recurrence of the disease allergies in patients who have experienced a first episode and that should continue some kind of treatment not directed against C. difficile allergies 2 , 4. Certainly the cost of fidaxomicin (1500 Ɛ treatment 10 days) is a limitation allergies to their prescription, so that care would be necessary evaluation of indication. .Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial patients With With C. difficile infection. Antimicrob Agents Chemother. 2009; 53: 223-8. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K. fidaxomicin versus vancomycin for Clostridium difficile infection in Europe With, Canada, and the USA: a double-blind, non-inferiority, randomized controlled trial. Lancet Infect Dis. 2012; 12: 281-9. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y. fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011.; 364: 422-31. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012; 55 (Suppl 2): S154-61.
Lost Password allergies Statistics 8 This item: 22749 Total Readings: 18 Readings Today: 15474 Total Views: 47 visitors per day: 1 Visitors Online: Contact allergies
No comments:
Post a Comment